Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

Overview of attention for article published in New England Journal of Medicine, January 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news: 59 news outlets
blogs: 2 blogs
policy: 8 policy sources
twitter: 155 X users
patent: 38 patents
facebook: 15 Facebook pages

wikipedia: 7 Wikipedia pages
f1000: 1 research highlight platform
video: 1 YouTube creator
guideline: 11 clinical guideline sources
podcasts: 6 podcasts

Readers on

mendeley: 1611 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 189 X posts from 155 X users, with an upper bound of 1,905,223 followers.

Sources: https://t.co/u3eb1jMYpe https://t.co/EkihTH0cnz https://t.co/lQ9yjqlggd https://t.co/aj4jFPDjik

RT @RobertJ09323900: @superpower Pancreatic Cancer Action says actinium 225 does work, & is likely a serious treatment for 2 deadly near 10…

@superpower Pancreatic Cancer Action says actinium 225 does work, & is likely a serious treatment for 2 deadly near 100% fatal cancers. At least 5 years out though, major issues about production, storage and shipping of a radionuclide with a half li…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 185 additional X posts.